DK3452100T3 - FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI - Google Patents

FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI Download PDF

Info

Publication number
DK3452100T3
DK3452100T3 DK17725186.5T DK17725186T DK3452100T3 DK 3452100 T3 DK3452100 T3 DK 3452100T3 DK 17725186 T DK17725186 T DK 17725186T DK 3452100 T3 DK3452100 T3 DK 3452100T3
Authority
DK
Denmark
Prior art keywords
mirnaues
hyperglychemia
treatment
diseases caused
pharmaceutical carriers
Prior art date
Application number
DK17725186.5T
Other languages
English (en)
Inventor
Maria Felice Brizzi
Giovanni Camussi
Original Assignee
Unicyte Ev Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unicyte Ev Ag filed Critical Unicyte Ev Ag
Application granted granted Critical
Publication of DK3452100T3 publication Critical patent/DK3452100T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1664Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/407Liver; Hepatocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
DK17725186.5T 2016-05-06 2017-05-04 FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI DK3452100T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16168546 2016-05-06
PCT/EP2017/060612 WO2017191234A1 (en) 2016-05-06 2017-05-04 Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia

Publications (1)

Publication Number Publication Date
DK3452100T3 true DK3452100T3 (da) 2021-03-08

Family

ID=56008484

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17725186.5T DK3452100T3 (da) 2016-05-06 2017-05-04 FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI

Country Status (13)

Country Link
US (2) US10716813B2 (da)
EP (2) EP3452100B1 (da)
JP (1) JP7011605B2 (da)
KR (1) KR102467150B1 (da)
CN (1) CN109195637B (da)
AU (1) AU2017260660B2 (da)
BR (1) BR112018072797A2 (da)
CA (1) CA3022921A1 (da)
DK (1) DK3452100T3 (da)
EA (1) EA037967B1 (da)
ES (1) ES2861650T3 (da)
PL (1) PL3452100T3 (da)
WO (1) WO2017191234A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI690320B (zh) 2010-05-12 2020-04-11 開曼群島商英瑞金公司 生物活性腎細胞
CN111601890B (zh) * 2017-12-14 2024-04-19 联合细胞Ev股份公司 用于治疗肾癌的包含miRNA的药物载体
US20210386786A1 (en) * 2018-08-31 2021-12-16 Timothy A. Bertram Compositions comprising cell-delivered vesicles and uses thereof
EP3980526A1 (en) * 2019-06-10 2022-04-13 Unicyte EV AG Extracellular vesicles from human liver stem cells (hlsc-evs) for reducing cellular senescence
CN115463107A (zh) * 2021-06-10 2022-12-13 中山大学 一种工程化囊泡的制备方法及其应用
US20240309329A1 (en) * 2023-03-17 2024-09-19 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived exosome drug delivery for cancer and other disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001280551B9 (en) * 2000-07-13 2006-01-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ic
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
SI2254586T1 (sl) * 2008-02-22 2015-07-31 Agency For Science, Technology And Research (A*Star) Delci mezenhimske matične celice
WO2010151640A2 (en) 2009-06-24 2010-12-29 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
CA2780222C (en) * 2009-11-04 2021-11-16 Diamir, Llc Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
TWI690320B (zh) 2010-05-12 2020-04-11 開曼群島商英瑞金公司 生物活性腎細胞
WO2012020308A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Cellular and molecular therapies
KR101993027B1 (ko) * 2012-04-03 2019-09-30 레뉴런 리미티드 줄기 세포 마이크로입자
SG11201500329WA (en) 2012-07-19 2015-02-27 Reneuron Ltd Stem cell microparticles
DK3016665T3 (da) * 2013-07-05 2019-11-25 Univ Catholique Louvain Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
US20170298352A1 (en) * 2014-09-30 2017-10-19 Research Institute at Nationwide Children's Hospit al Compositions and methods for treating hepatic fibrosis
US10881683B2 (en) 2015-09-16 2021-01-05 Tohoku University Nucleic acid molecule

Also Published As

Publication number Publication date
EP3452100B1 (en) 2020-12-16
US10716813B2 (en) 2020-07-21
ES2861650T3 (es) 2021-10-06
EP3777897A2 (en) 2021-02-17
EA201892536A1 (ru) 2019-04-30
EP3452100A1 (en) 2019-03-13
CN109195637B (zh) 2022-08-09
US20190209619A1 (en) 2019-07-11
KR20190005209A (ko) 2019-01-15
JP2019514964A (ja) 2019-06-06
CN109195637A (zh) 2019-01-11
CA3022921A1 (en) 2017-11-09
JP7011605B2 (ja) 2022-01-26
PL3452100T3 (pl) 2021-07-19
WO2017191234A1 (en) 2017-11-09
BR112018072797A2 (pt) 2019-03-12
EP3777897A3 (en) 2021-06-09
AU2017260660B2 (en) 2023-12-21
US11110130B2 (en) 2021-09-07
EA037967B1 (ru) 2021-06-16
AU2017260660A1 (en) 2018-12-20
KR102467150B1 (ko) 2022-11-14
US20200222467A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3383363T3 (da) Topiske farmaceutiske formuleringer til behandling af inflammatorisk-relaterede tilstande
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3139925T3 (da) Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
DK3452100T3 (da) FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
DK3237045T3 (da) Indretning til indgivelse af lægemidler
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3236935T3 (da) Farmaceutisk doseringsform til anvendelse på slimhinder
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser